Aquestive Says FDA Accepts Anaphylm NDA Resubmission For The Treatment Of Type I Allergic Reactions

Aquestive Therapeutics (AQST) announced the FDA accepted its resubmission for Anaphylm, a treatment for Type I allergic reactions. The FDA set a PDUFA goal date of March 16, 2027. The resubmission follows positive study results addressing prior FDA concerns. If approved, Anaphylm would be the first oral rescue medication for severe allergic reactions.

Original reporting
Published Oct 15, 2026, 11:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 11:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$AQST
Bullish
high confidence
Mentioned
$AQST
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$AQSTBullishMed
01

Why it matters

The FDA's Class 2 response and PDUFA date provide a clear timeline, reducing regulatory uncertainty and potentially attracting new capital.

02

Market read

Regulatory progress for a novel oral anaphylaxis treatment could move AQST shares and influence related biotech valuations.

03

What to watch

Potential competition from injectable epinephrine products and reimbursement uncertainties.

Relevance 7/10Novelty 8/10Timing: today

Background

Aquestive Therapeutics is a Nasdaq‑listed biotech developing Anaphylm, a sublingual film for severe allergic reactions.

Company-level read

Ticker impact

$AQSTBullishHigh confidence
Context

FDA accepted the NDA resubmission for Anaphylm, setting a PDUFA target of March 16, 2027.

Expected impact

potential upside as investors price in a likely approval if trials remain successful

Evidence & confidence

Regulatory acceptance is a material catalyst for a micro‑cap biotech; market typically reacts positively to forward‑looking FDA milestones.

Market effects

May boost sentiment for allergy‑treatment and oral‑delivery biotech peers.

U.S. biotech sector could see modest lift in small‑cap indices.

Limited to investors tracking FDA pipeline developments.

Counterpoint

If clinical data later reveal safety concerns, the FDA acceptance may not translate into price gains.

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharmaceutical developer of Anaphylm.

  • U.S. Food and Drug Administration

    Agency that accepted the NDA resubmission.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.